News

Novartis' Afinitor extends progression-free survival in NET


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Novartis' Afinitor extends progression-free survival in NET


 

Date: 22/05/2015


Novartis says late-stage clinical data show that its cancer drug Afinitor extended progression-free survival in patients with advanced nonfunctional neuroendocrine tumours (NET) of gastrointestinal or lung origin.

A Phase III trial of the drug - called RADIANT-4 - met its primary endpoint by demonstrating significant extension of progression-free survival (PFS) compared to placebo plus best supportive care.

For more click here

Source: Pharma Times

© Catalyst Innovation Portal 2019